Syncrosome as Event Partner of 3rd HF Drug Discovery & Development Summit in Boston
Syncrosome is proud to attend the next Heart Failure Drug Discovery & Development Summit as an event partner, which will take place from 31 July to 1 August 2024, in Boston (USA, MA)!
We look forward to participating in the 3rd HF Drug Discovery & Development Summit, which returns to tackle the major challenges facing preclinical heart failure drug development by bringing together more than 50 biopharmas delve into targeting, stratifying and treating cardiomyopathies with greater precision.
A fine programme of scientific conferences and poster sessions in prospect! SYNCROSOME, as the cardiology branch of ETAP-Lab, will be presenting a poster on original cardiovascular preclinical results.
📆 Let’s meet at our scientific poster session
Our team will present our original results supporting development for HF & cardiomyopathies.
Come and discover our poster and see you on 31 July 2024 at 4.25 am on day 1.
🫀 Our cardiovascular models, tailored to your HF challenges.
Would you like to accelerate the development of your cardiology drugs and/or medical devices through preclinical studies ?
At ETAP-Lab – a French preclinical CRO for over 30 years – we can accelerate, derisk and support pharmaceutical companies‘ preclinical development with relevant and translatable in vitro and in vivo models !
We offer a wide range of services dedicated to modelling cardiovascular diseases such as HFrEF, HFpEF, acute myocardial ischaemia and arterial/pulmonary hypertension…
More to discover:
- Have a look at our wide range of models in Cardiology !
- You can connect with us at marketing@etap-lab.com and ask for the poster in PDF.
- Discover the HF Summit
